GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (FRA:12V) » Definitions » Cyclically Adjusted PB Ratio

Veracyte (FRA:12V) Cyclically Adjusted PB Ratio : 2.91 (As of Jun. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte Cyclically Adjusted PB Ratio?

As of today (2024-06-05), Veracyte's current share price is €19.20. Veracyte's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €6.60. Veracyte's Cyclically Adjusted PB Ratio for today is 2.91.

The historical rank and industry rank for Veracyte's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:12V' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.63   Med: 4.15   Max: 11.48
Current: 2.9

During the past years, Veracyte's highest Cyclically Adjusted PB Ratio was 11.48. The lowest was 2.63. And the median was 4.15.

FRA:12V's Cyclically Adjusted PB Ratio is ranked worse than
65.91% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.995 vs FRA:12V: 2.90

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Veracyte's adjusted book value per share data for the three months ended in Mar. 2024 was €13.466. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €6.60 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Veracyte Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Veracyte's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Cyclically Adjusted PB Ratio Chart

Veracyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 11.46 4.39 3.97

Veracyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.89 4.14 3.34 3.97 3.02

Competitive Comparison of Veracyte's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Veracyte's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Veracyte's Cyclically Adjusted PB Ratio falls into.



Veracyte Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Veracyte's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=19.20/6.6
=2.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Veracyte's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=13.466/131.7762*131.7762
=13.466

Current CPI (Mar. 2024) = 131.7762.

Veracyte Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.545 100.560 2.025
201409 1.666 100.428 2.186
201412 1.490 99.070 1.982
201503 1.437 99.621 1.901
201506 2.102 100.684 2.751
201509 1.862 100.392 2.444
201512 1.699 99.792 2.244
201603 1.396 100.470 1.831
201606 1.078 101.688 1.397
201609 0.957 101.861 1.238
201612 1.673 101.863 2.164
201703 1.473 102.862 1.887
201706 1.256 103.349 1.601
201709 1.057 104.136 1.338
201712 0.919 104.011 1.164
201803 0.709 105.290 0.887
201806 0.641 106.317 0.794
201809 1.679 106.507 2.077
201812 1.716 105.998 2.133
201903 1.786 107.251 2.194
201906 4.113 108.070 5.015
201909 4.297 108.329 5.227
201912 4.343 108.420 5.279
202003 4.171 108.902 5.047
202006 3.981 108.767 4.823
202009 6.208 109.815 7.450
202012 5.949 109.897 7.133
202103 12.171 111.754 14.352
202106 11.947 114.631 13.734
202109 13.248 115.734 15.084
202112 13.644 117.630 15.285
202203 13.794 121.301 14.985
202206 14.068 125.017 14.829
202209 14.757 125.227 15.529
202212 14.105 125.222 14.843
202303 13.952 127.348 14.437
202306 13.757 128.729 14.083
202309 13.531 129.860 13.731
202312 13.068 129.419 13.306
202403 13.466 131.776 13.466

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Veracyte  (FRA:12V) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Veracyte Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Veracyte's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte (FRA:12V) Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.

Veracyte (FRA:12V) Headlines

No Headlines